T1	p 18 123	patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with
T2	p 401 447	patients with metastatic breast cancer ( MBC )
T3	p 636 643	n = 509
T4	i 124 172	doxorubicin or pegylated liposomal doxorubicin :
T5	i 314 396	chemotherapy with doxorubicin ( DOX ) or a pegylated liposomal formulation ( PLD )
T6	i 524 598	DOX ( 60 mg/m ( 2 ) every 3 weeks ) or PLD ( 50 mg/m ( 2 ) every 4 weeks )
T7	i 613 625	line therapy
T8	i 1378 1390	chemotherapy
T9	i 1393 1407	DOX versus PLD
T10	i 1813 1859	granulocyte colony stimulating factor or PLD )
T11	i 1938 1950	chemotherapy
T12	o 729 745	neutrophil count
T13	o 831 857	neutropenia or neutropenia
T14	o 1259 1277	performance status
T15	o 1280 1305	absolute neutrophil count
T16	o 1438 1448	risk score
T17	o 1527 1536	threshold
T18	o 1541 1552	sensitivity